The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity

Lempesis, Ioannis G.

doi:10.1016/j.metop.2022.100220

Cited by 14 publications

(4 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Mediterranean diet and, lately, ketogenic diets are increasingly being recognized as important parameters in the fight against obesity [ 145 , 146 , 147 ]. Besides the use of agents with weight loss properties, such as GLP-1 analogs or tirzepatide [ 148 , 149 ], which possess agonist activities in both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, there is an emerging interest in the use of NGPs. The advent of sophisticated molecular methods has revolutionized the study of NGPs as potential preventive and therapeutic anti-obesity agents.…”

Section: Discussionmentioning

confidence: 99%

The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives

Kounatidis

Tsilingiris

Panagopoulos

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Obesity and obesity-associated disorders pose a major public health issue worldwide. Apart from conventional weight loss drugs, next-generation probiotics (NGPs) seem to be very promising as potential preventive and therapeutic agents against obesity. Candidate NGPs such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Anaerobutyricum hallii, Bacteroides uniformis, Bacteroides coprocola, Parabacteroides distasonis, Parabacteroides goldsteinii, Hafnia alvei, Odoribacter laneus and Christensenella minuta have shown promise in preclinical models of obesity and obesity-associated disorders. Proposed mechanisms include the modulation of gut flora and amelioration of intestinal dysbiosis, improvement of intestinal barrier function, reduction in chronic low-grade inflammation and modulation of gut peptide secretion. Akkermansia muciniphila and Hafnia alvei have already been administered in overweight/obese patients with encouraging results. However, safety issues and strict regulations should be constantly implemented and updated. In this review, we aim to explore (1) current knowledge regarding NGPs; (2) their utility in obesity and obesity-associated disorders; (3) their safety profile; and (4) their therapeutic potential in individuals with overweight/obesity. More large-scale, multicentric and longitudinal studies are mandatory to explore their preventive and therapeutic potential against obesity and its related disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives

Kounatidis

Tsilingiris

Panagopoulos

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Notably, the world witnessed the miracles of other 'jabs' for obesity, the arising family of injectable incretin analogues, with a secondary, yet highly favorable outcome, resulting in outstanding weight loss comparable to bariatric and metabolic surgical procedures (29)(30)(31)(32). Anti-obesity medications were the result of decades of research, proceeding at a much slower pace than those of COVID-19, demonstrating that wherever there is a will, there is a way (30). There is a possibility of prejudice against individuals who are obese both inside and outside of the scientific community.…”

Section: The Interconnectedness Of Covid-19 and Obesitymentioning

confidence: 99%

The parallel lives of pandemics: COVID‑19 and obesity

Georgakopoulou,

Lempesis,

Spandidos

2024

Exp Ther Med

View full text Add to dashboard Cite

The present article discusses the interconnectedness of coronavirus disease 2019 (COVID-19) and obesity as global health crises. The similarities between the two conditions are highlighted; these include shared risk factors and comorbidities, and the impact of obesity on the immune system. The present article also mentions the challenges faced in combating both pandemics, including misinformation and prejudice against obesity. It discusses the development of therapeutic medications and vaccines for COVID-19 and the potential of injectable incretin analogues for weight loss. Socioeconomic issues are also addressed, with obesity being more prevalent in lower socioeconomic groups and the cost of obesity treatments being a barrier for those in need. The present article emphasizes the need for comprehensive and sustainable solutions, including public health interventions, education, policy changes and equitable distribution of resources, to address both COVID-19 and obesity.

show abstract

“…Curiosamente, foi demonstrado que a tirzepatida eleva os níveis de adiponectina, uma adipocina sensibilizadora à insulina implicada na regulação do metabolismo da glicose e lipídico. A tirzepatida melhorou o controle glicêmico e o peso corporal sem aumentar o risco de hipoglicemia, um perfil de segurança comparável aos agonistas do receptor GLP-1 (Lempesis;Liu;Dalamaga, 2022). A tirzepatida reduziu a HbA1c, FSG, o peso corporal e a pressão arterial, melhorou os perfis lipídicos de jejum.…”

Section: Para a Construção Da Revisão Integrativa Foram Seguidos Os S...unclassified

Tirzepatida, Agonista Do Receptor Duplo De Gip E GLP-1, No Tratamento De Diabetes Mellitus Tipo 2: Eficácia E Segurança

Alvarenga Bastos,

Bonfim Lopes,

Vargas Olivieri

et al. 2024

RECIMA21

View full text Add to dashboard Cite

A diabetes mellitus tipo 2 (DM2) é uma condição crônica caracterizada por resistência à insulina e deficiência na produção de insulina pelo pâncreas. O tratamento da diabetes mellitus tipo 2 é geralmente individualizado e visa controlar efetivamente os níveis de glicose no sangue, minimizar complicações e melhorar a qualidade de vida dos pacientes. A tirzepatida é um agonista bifuncional do receptor de GLP-1 e glucagon com potencial para revolucionar o tratamento da diabetes mellitus tipo 2. Objetivos: fornecer uma visão abrangente do papel da tirzepatida no arsenal terapêutico atual da diabetes mellitus tipo 2, focando em sua eficácia e segurança. Materiais e métodos: Trata-se de uma revisão integrativa, em que a questão norteadora foi “A tirzepatida é segura e eficaz no tratamento de diabetes mellitus tipo 2?”. A busca pelos artigos ocorreu nas principais bases de dados (PubMed e Scielo) a partir dos termos "tirzepatide", "treatment" e "type 2 diabetes" combinados entre si por operadores booleanos. Resultados e discussão: A tirzepatida é o primeiro agonista de receptor duplo que foi recentemente aprovado para o tratamento da DM2 pela Food Drug Administration (FDA). A eficácia em relação à redução da glicemia e do peso corporal é mais forte do que a dos GLP-1, enquanto o perfil de segurança e a incidência de eventos adversos parecem comparáveis. Conclusão: A tirzepatida é uma nova terapia à base de incretina para DM2, ela mostrou reduções robustas de HbA1c e peso corporal, sem um risco aumentado de hipoglicemia.

show abstract

The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity

Cited by 14 publications

References 68 publications

The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives

The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives

The parallel lives of pandemics: COVID‑19 and obesity

Tirzepatida, Agonista Do Receptor Duplo De Gip E GLP-1, No Tratamento De Diabetes Mellitus Tipo 2: Eficácia E Segurança

Contact Info

Product

Resources

About